Treatment of Hepatocellular Carcinoma with Neoadjuvant Nivolumab Alone Versus in Combination with a CCR2/5 Inhibitor or an Anti-IL-8 Antibody

Ann Surg Oncol. 2022 Jan;29(1):30-32. doi: 10.1245/s10434-021-10269-7. Epub 2021 Jun 11.

Authors

Alexander J Rossi¹, Tahsin M Khan¹, Areeba Saif¹, Thomas U Marron², Jonathan M Hernandez³

Affiliations

¹ Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
² Early Phase Trials Unit, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. [email protected].
³ Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. [email protected].

PMID: 34117573
DOI: 10.1245/s10434-021-10269-7

No abstract available

Publication types

Letter

MeSH terms

Carcinoma, Hepatocellular* / drug therapy
Humans
Ipilimumab
Liver Neoplasms* / drug therapy
Neoadjuvant Therapy
Nivolumab / therapeutic use
Receptors, CCR2

Substances

CCR2 protein, human
Ipilimumab
Receptors, CCR2
Nivolumab